查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
结合疫苗全球市场规模调查和预测：按疾病适应症、病原体类型、最终用户、地区2022-2029
市场调查报告书
商品编码
1215431

结合疫苗全球市场规模调查和预测：按疾病适应症、病原体类型、最终用户、地区2022-2029

Global Conjugate Vaccines Market Size study & Forecast, by Type by Disease Indication, by Pathogen Type, by End User and Regional Analysis, 2022-2029
出版日期: | 出版商: Bizwit Research & Consulting LLP | 英文 | 商品交期: 2-3个工作天内

价格

结合疫苗是一种亚单位疫苗，将强抗原作为载体与弱抗原结合，增强对弱抗原的免疫反应。

疫苗用于通过增强对抗原的免疫反应来抵御 b 型流感嗜血桿菌 (Hib) 和肺炎链球菌等疾病。 政府的批准和肺炎球菌疾病全球流行率的上升是推动结合疫苗市场增长的主要因素。 因此，它可以在预测期内为市场产生有利可图的需求。

结合疫苗广泛用于预防肺炎球菌疾病。 因此，预计肺炎球菌疾病患病率的增加将在预测期内推动市场需求。 根据世界卫生组织的数据，2019 年肺炎导致 7,40,180 名五岁以下儿童死亡，占该年龄组所有儿童死亡人数的 14%，但所有 1 至 5 岁儿童死亡人数占所有儿科医生死亡人数的 22%。 世界各地的儿童和家庭都受到肺炎的影响，但南亚和撒哈拉以南非洲的死亡率最高。 在市场参与者推出新产品的推动下，政府也越来越多地批准结合疫苗来控制各类疾病的传播。 例如，2020 年 4 月，美国食品和药物管理局 (FDA) 批准了 MenQuadfi 脑膜炎球菌结合疫苗的生物製品许可申请，□□用于治疗 2 岁及以上人群的侵袭性脑膜炎球菌病。 此外，在预测期内，为开发有效疫苗而进行的持续研发活动将为市场创造有利可图的机会。 然而，与结合疫苗相关的副作用增加将阻碍整个 2022-2029 年预测期内的市场增长。

全球结合疫苗市场研究考虑的主要区域包括亚太地区、北美、欧洲、拉丁美洲和世界其他地区。 由于该地区復杂医疗保健支出的增加和患者警惕性水平的提高，北美已成为世界市场份额的主导地区。 另一方面，由于主要市场参与者的存在以及政府对疫苗开发的支持增加等因素，预计亚太地区在预测期内将呈现高增长率。产生有利可图的增长前景

这项研究的目的是定义近年来各个细分市场和国家的市场规模，并预测未来几年的价值。 本报告旨在捕捉被调查国家行业的定性和定量方面的情况。

它还提供了关键方面的详细信息，例如决定市场未来增长的驱动因素和挑战。 此外，它还包含供利益相关者投资的微观市场潜在机会，以及对主要参与者的竞争格局和产品供应的深入分析。

内容

第 1 章执行摘要

  • 市场概况
  • 2019-2029 年全球市场和细分的市场估计和预测
    • 结合疫苗市场：按地区划分，2019-2029 年
    • 2019-2029 年按类型划分的结合疫苗市场
    • 结合疫苗市场：按疾病适应症分类，2019-2029 年
    • 结合疫苗市场：按病原体类型，2019-2029 年
    • 结合疫苗市场：按最终用户分类，2019-2029 年
  • 主要趋势
  • 调查方法
  • 调查先决条件

第 2 章结合疫苗的全球市场定义和范围

  • 调查的目的
  • 市场定义和范围
    • 调查范围
    • 工业发展
  • 调查年份
  • 货币兑换率

第3章结合疫苗全球市场动态

  • 结合疫苗市场影响分析 (2019-2029)
    • 市场驱动力
      • 政府对结合疫苗的批准增加
      • 肺炎球菌疾病的流行率上升
    • 市场挑战
      • 与结合疫苗相关的副作用增加
    • 市场机会
      • 为有效开发疫苗而进行的持续研发活动

第四章全球疫苗市场行业分析

  • 波特 5 力模型
    • 供应商的议价能力
    • 买家的议价能力
    • 新进入者的威胁
    • 替代品的威胁
    • 竞争公司之间的敌对关係
  • 波特 5 力模型的未来方法 (2019-2029)
  • 害虫分析
    • 政治
    • 经济的
    • 社交
    • 技术
  • 投资招聘模式
  • 分析师的结论和建议
  • 顶级投资机会
  • 关键成功策略

第 5 章风险评估：COVID-19 的影响

  • 评估 COVID-19 对行业的总体影响
  • COVID-19 之前和 COVID-19 之后的市场情景

第 6 章全球结合疫苗市场，按类型

  • 市场概况
  • 结合疫苗的世界市场：按类型分类的性能 - 潜力分析
  • 2019-2029 年按类型分列的结合疫苗全球市场估计和预测
  • 全球结合疫苗市场细分分析
    • 单价结合疫苗
    • 多价结合疫苗

第 7 章：全球结合疫苗市场：按疾病和适应症分类

  • 市场概况
  • 结合疫苗的世界市场：按疾病、性能和潜力分析
  • 2019-2029 年世界结合疫苗市场、按疾病适应症估计和预测
  • 结合疫苗市场，细分分析
    • 肺炎球菌
    • 流感
    • 白喉破伤风百日咳 (DTP)
    • 脑膜炎球菌
    • 其他

第 8 章全球结合疫苗市场：按病原体类型分类

  • 市场概况
  • 结合疫苗的全球市场：按病原体类型、性能和潜力分析
  • 世界结合疫苗市场，按病原体类型估计和预测（2019-2029）
  • 结合疫苗市场，细分分析
    • 细菌结合疫苗
    • 病毒结合疫苗
    • 混合（病毒和细菌）结合疫苗

第 9 章结合疫苗的全球市场：按最终用户分类

  • 市场概况
  • 结合疫苗的世界市场：最终用户的性能潜力分析
  • 2019-2029 年全球结合疫苗市场、最终用户估计和预测
  • 结合疫苗市场，细分分析
    • 儿科
    • 对于成年人

第 10 章全球结合疫苗市场：区域分析

  • 结合疫苗市场，按地区划分的市场概况
  • 北美
    • 美国
      • 按类型估算和预测，2019-2029 年
      • 按疾病适应症估算和预测，2019-2029 年
      • 按病原体类型估算和预测，2019-2029 年
      • 2019-2029 年最终用户的估计和预测
    • 加拿大
  • 欧洲结合疫苗市场概况
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 意大利
    • 其他欧洲地区
  • 亚太地区结合疫苗市场概况
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 韩国
    • 其他亚太地区
  • 拉丁美洲结合疫苗市场概况
    • 巴西
    • 墨西哥
  • 世界其他地区

第 11 章衝突信息

  • 顶级市场策略
  • 公司简介
    • 诺华公司
      • 主要信息
      • 概览
      • 财务信息（取决于数据可用性）
      • 产品概述
      • 近期趋势
    • Neuron Biotech
    • Serum Institute of India
    • Pfizer, Inc.
    • Sanofi Pasteur
    • Bharat Biotech
    • Biological E Ltd.
    • GlaxoSmithKline, plc.
    • Merck and Company
    • CSL Limited

第 12 章研究过程

  • 研究过程
    • 数据挖掘
    • 分析
    • 市场评估
    • 验证
    • 出版
  • 调查属性
  • 调查先决条件

Global Conjugate Vaccines Market is valued approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. A conjugate vaccine is a kind of subunit vaccine that uses a strong antigen as a carrier to combine a weak antigen with, thus enhancing the immune system's response to the weak antigen. By enhancing an immune response to an antigen, vaccines are used to avoid diseases like Haemophilus influenzae B (Hib), pneumococcus and others. The key factor driving the market growth of conjugate vaccines is rising government approvals and prevalence of pneumococcal disease globally. Thus, create the lucrative demand for the market during forecast period.

The Conjugate Vaccines is widely used to avoid pneumococcus diseases. Thus, the increasing prevalence of pneumococcus diseases is anticipated to propelling demand for the market during forecast period. According to WHO, 7,40,180 children under the age of five died from pneumonia in 2019, accounting for 14% of all child deaths in that age group but 22% of all pediatric deaths in children from 1 to 5. Children and families worldwide are affected by pneumonia, but South Asia and sub-Saharan Africa have the highest death rates. Also, the rising government approval for Conjugate Vaccines to control the rising prevalence of various types of disease and encouraging market players for introducing a new product. For instance, in April 2020, U.S. Food and Drug Administration (FDA) approved the MenQuadfi Meningococcal Conjugate Vaccine's Biologics License Application for the treatment of invasive meningococcal disease in people two years of age and older. Also, the constant R&D activities for the development of effective vaccines would create the lucrative opportunity for the market during forecast period. However, the rising side effects associated with the conjugate vaccine stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Conjugate Vaccines Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the dominating region across the world in terms of market share, owing to the occurrence of the refined healthcare expenses and increasing the patient alertness level in the region. Whereas, Asia Pacific is also anticipated to exhibit highest growth rate over the forecast period, owing to factors such as presence of key market players and increasing support from the government for the vaccine development would create lucrative growth prospects for the Conjugate Vaccines market across Asia Pacific region.

Major market players included in this report are:

Novartis AG

Neuron Biotech

Serum Institute of India

Pfizer, Inc.

Sanofi Pasteur

Bharat Biotech

Biological E Ltd.

GlaxoSmithKline, plc.

Merck and Company

CSL Limited

Recent Developments in the Market:

  • In June 2021, Pfizer Inc. announced that the FDA has approved PREVNAR 20TM (Pneumococcal 20-valent Conjugate Vaccine) for use in people 18 years of age and older to prevent pneumonia and invasive disease brought on by the 20 pneumococcal serotypes contained in the vaccine.
  • In July 2021, Kenilworth, also known as MSD outside of the USA and Canada, announced that the U.S. Food and Drug Administration (FDA) had approved VAXNEUVANCETM (Pneumococcal 15-valent Conjugate Vaccine) (pronounced VAKS-noo-vans) for use in adults 18 years of age and older as an immunization for the prevention of invasive disease caused by streptococcus pneumoniae.

Global Conjugate Vaccines Market Report Scope:

Historical Data: 2019-2020-2021

Base Year for Estimation: 2021

Forecast period: 2022-2029

Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends

Segments Covered: Type, Disease Indication, Pathogen Type, End User, Region

Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World

Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type:

Monovalent Conjugate Vaccines

Multivalent Conjugate Vaccines

By Disease Indication:

Pneumococcal

Influenza

Diphtheria Tetanus and Pertussis (DTP)

Meningococcal

Others

By Pathogen Type:

Bacterial Conjugate Vaccine

Viral Conjugate Vaccine

Combination (Viral and Bacterial) Conjugate Vaccine

By End User:

Pediatrics

Adults

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
    • 1.2.1. Conjugate Vaccines Market, by Region, 2019-2029 (USD Billion)
    • 1.2.2. Conjugate Vaccines Market, by Type, 2019-2029 (USD Billion)
    • 1.2.3. Conjugate Vaccines Market, by Disease Indication, 2019-2029 (USD Billion)
    • 1.2.4. Conjugate Vaccines Market, by Pathogen Type, 2019-2029 (USD Billion)
    • 1.2.5. Conjugate Vaccines Market, by End User, 2019-2029 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Conjugate Vaccines Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Conjugate Vaccines Market Dynamics

  • 3.1. Conjugate Vaccines Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Rising Government Approvals for Conjugate Vaccines
      • 3.1.1.2. Rising Prevalence of Pneumococcal Disease
    • 3.1.2. Market Challenges
      • 3.1.2.1. Rising side effects associated with the conjugate vaccine
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Constant R&D activities for the development of effective vaccines

Chapter 4. Global Conjugate Vaccines Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Investment Adoption Model
  • 4.5. Analyst Recommendation & Conclusion
  • 4.6. Top investment opportunity
  • 4.7. Top winning strategies

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Conjugate Vaccines Market, by Type

  • 6.1. Market Snapshot
  • 6.2. Global Conjugate Vaccines Market by Type, Performance - Potential Analysis
  • 6.3. Global Conjugate Vaccines Market Estimates & Forecasts by Type 2019-2029 (USD Billion)
  • 6.4. Conjugate Vaccines Market, Sub Segment Analysis
    • 6.4.1. Monovalent Conjugate Vaccines
    • 6.4.2. Multivalent Conjugate Vaccines

Chapter 7. Global Conjugate Vaccines Market, by Disease Indication

  • 7.1. Market Snapshot
  • 7.2. Global Conjugate Vaccines Market by Disease Indication, Performance - Potential Analysis
  • 7.3. Global Conjugate Vaccines Market Estimates & Forecasts by Disease Indication 2019-2029 (USD Billion)
  • 7.4. Conjugate Vaccines Market, Sub Segment Analysis
    • 7.4.1. Pneumococcal
    • 7.4.2. Influenza
    • 7.4.3. Diphtheria Tetanus and Pertussis (DTP)
    • 7.4.4. Meningococcal
    • 7.4.5. Others

Chapter 8. Global Conjugate Vaccines Market, by Pathogen Type

  • 8.1. Market Snapshot
  • 8.2. Global Conjugate Vaccines Market by Pathogen Type, Performance - Potential Analysis
  • 8.3. Global Conjugate Vaccines Market Estimates & Forecasts by Pathogen Type 2019-2029 (USD Billion)
  • 8.4. Conjugate Vaccines Market, Sub Segment Analysis
    • 8.4.1. Bacterial Conjugate Vaccine
    • 8.4.2. Viral Conjugate Vaccine
    • 8.4.3. Combination (Viral and Bacterial) Conjugate Vaccine

Chapter 9. Global Conjugate Vaccines Market, by End User

  • 9.1. Market Snapshot
  • 9.2. Global Conjugate Vaccines Market by End User, Performance - Potential Analysis
  • 9.3. Global Conjugate Vaccines Market Estimates & Forecasts by End User 2019-2029 (USD Billion)
  • 9.4. Conjugate Vaccines Market, Sub Segment Analysis
    • 9.4.1. Pediatrics
    • 9.4.2. Adults

Chapter 10. Global Conjugate Vaccines Market, Regional Analysis

  • 10.1. Conjugate Vaccines Market, Regional Market Snapshot
  • 10.2. North America Conjugate Vaccines Market
    • 10.2.1. U.S. Conjugate Vaccines Market
      • 10.2.1.1. Type breakdown estimates & forecasts, 2019-2029
      • 10.2.1.2. Disease Indication breakdown estimates & forecasts, 2019-2029
      • 10.2.1.3. Pathogen Type breakdown estimates & forecasts, 2019-2029
      • 10.2.1.4. End User breakdown estimates & forecasts, 2019-2029
    • 10.2.2. Canada Conjugate Vaccines Market
  • 10.3. Europe Conjugate Vaccines Market Snapshot
    • 10.3.1. U.K. Conjugate Vaccines Market
    • 10.3.2. Germany Conjugate Vaccines Market
    • 10.3.3. France Conjugate Vaccines Market
    • 10.3.4. Spain Conjugate Vaccines Market
    • 10.3.5. Italy Conjugate Vaccines Market
    • 10.3.6. Rest of Europe Conjugate Vaccines Market
  • 10.4. Asia-Pacific Conjugate Vaccines Market Snapshot
    • 10.4.1. China Conjugate Vaccines Market
    • 10.4.2. India Conjugate Vaccines Market
    • 10.4.3. Japan Conjugate Vaccines Market
    • 10.4.4. Australia Conjugate Vaccines Market
    • 10.4.5. South Korea Conjugate Vaccines Market
    • 10.4.6. Rest of Asia Pacific Conjugate Vaccines Market
  • 10.5. Latin America Conjugate Vaccines Market Snapshot
    • 10.5.1. Brazil Conjugate Vaccines Market
    • 10.5.2. Mexico Conjugate Vaccines Market
  • 10.6. Rest of The World Conjugate Vaccines Market

Chapter 11. Competitive Intelligence

  • 11.1. Top Market Strategies
  • 11.2. Company Profiles
    • 11.2.1. Novartis AG
      • 11.2.1.1. Key Information
      • 11.2.1.2. Overview
      • 11.2.1.3. Financial (Subject to Data Availability)
      • 11.2.1.4. Product Summary
      • 11.2.1.5. Recent Developments
    • 11.2.2. Neuron Biotech
    • 11.2.3. Serum Institute of India
    • 11.2.4. Pfizer, Inc.
    • 11.2.5. Sanofi Pasteur
    • 11.2.6. Bharat Biotech
    • 11.2.7. Biological E Ltd.
    • 11.2.8. GlaxoSmithKline, plc.
    • 11.2.9. Merck and Company
    • 11.2.10. CSL Limited

Chapter 12. Research Process

  • 12.1. Research Process
    • 12.1.1. Data Mining
    • 12.1.2. Analysis
    • 12.1.3. Market Estimation
    • 12.1.4. Validation
    • 12.1.5. Publishing
  • 12.2. Research Attributes
  • 12.3. Research Assumption

LIST OF TABLES

  • TABLE 1. Global Conjugate Vaccines Market, report scope
  • TABLE 2. Global Conjugate Vaccines Market estimates & forecasts by Region 2019-2029 (USD Billion)
  • TABLE 3. Global Conjugate Vaccines Market estimates & forecasts by Type 2019-2029 (USD Billion)
  • TABLE 4. Global Conjugate Vaccines Market estimates & forecasts by Disease Indication 2019-2029 (USD Billion)
  • TABLE 5. Global Conjugate Vaccines Market estimates & forecasts by Pathogen Type 2019-2029 (USD Billion)
  • TABLE 6. Global Conjugate Vaccines Market estimates & forecasts by End User 2019-2029 (USD Billion)
  • TABLE 7. Global Conjugate Vaccines Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 8. Global Conjugate Vaccines Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 9. Global Conjugate Vaccines Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 10. Global Conjugate Vaccines Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 11. Global Conjugate Vaccines Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 12. Global Conjugate Vaccines Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 13. Global Conjugate Vaccines Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 14. Global Conjugate Vaccines Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 15. Global Conjugate Vaccines Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 16. Global Conjugate Vaccines Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 17. U.S. Conjugate Vaccines Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 18. U.S. Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 19. U.S. Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 20. Canada Conjugate Vaccines Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 21. Canada Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 22. Canada Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 23. UK Conjugate Vaccines Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 24. UK Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 25. UK Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 26. Germany Conjugate Vaccines Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 27. Germany Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 28. Germany Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 29. France Conjugate Vaccines Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 30. France Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 31. France Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 32. Italy Conjugate Vaccines Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 33. Italy Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 34. Italy Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 35. Spain Conjugate Vaccines Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 36. Spain Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 37. Spain Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 38. RoE Conjugate Vaccines Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 39. RoE Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 40. RoE Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 41. China Conjugate Vaccines Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 42. China Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 43. China Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 44. India Conjugate Vaccines Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 45. India Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 46. India Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 47. Japan Conjugate Vaccines Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 48. Japan Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 49. Japan Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 50. South Korea Conjugate Vaccines Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 51. South Korea Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 52. South Korea Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 53. Australia Conjugate Vaccines Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 54. Australia Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 55. Australia Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 56. RoAPAC Conjugate Vaccines Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 57. RoAPAC Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 58. RoAPAC Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 59. Brazil Conjugate Vaccines Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 60. Brazil Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 61. Brazil Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 62. Mexico Conjugate Vaccines Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 63. Mexico Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 64. Mexico Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 65. RoLA Conjugate Vaccines Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 66. RoLA Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 67. RoLA Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 68. Row Conjugate Vaccines Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 69. Row Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 70. Row Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 71. List of secondary sources, used in the study of global Conjugate Vaccines Market
  • TABLE 72. List of primary sources, used in the study of global Conjugate Vaccines Market
  • TABLE 73. Years considered for the study
  • TABLE 74. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global Conjugate Vaccines Market, research methodology
  • FIG 2. Global Conjugate Vaccines Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Conjugate Vaccines Market, key trends 2021
  • FIG 5. Global Conjugate Vaccines Market, growth prospects 2022-2029
  • FIG 6. Global Conjugate Vaccines Market, porters 5 force model
  • FIG 7. Global Conjugate Vaccines Market, pest analysis
  • FIG 8. Global Conjugate Vaccines Market, value chain analysis
  • FIG 9. Global Conjugate Vaccines Market by segment, 2019 & 2029 (USD Billion)
  • FIG 10. Global Conjugate Vaccines Market by segment, 2019 & 2029 (USD Billion)
  • FIG 11. Global Conjugate Vaccines Market by segment, 2019 & 2029 (USD Billion)
  • FIG 12. Global Conjugate Vaccines Market by segment, 2019 & 2029 (USD Billion)
  • FIG 13. Global Conjugate Vaccines Market by segment, 2019 & 2029 (USD Billion)
  • FIG 14. Global Conjugate Vaccines Market, regional snapshot 2019 & 2029
  • FIG 15. North America Conjugate Vaccines Market 2019 & 2029 (USD Billion)
  • FIG 16. Europe Conjugate Vaccines Market 2019 & 2029 (USD Billion)
  • FIG 17. Asia pacific Conjugate Vaccines Market 2019 & 2029 (USD Billion)
  • FIG 18. Latin America Conjugate Vaccines Market 2019 & 2029 (USD Billion)
  • FIG 19. Global Conjugate Vaccines Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable